APIS Assay Technologies Ltd
APIS Assay Technologies is leveraging systems biology, interrogating multi-OMICs biodata, and deploying innovative 'Clickmer' ligand binding technology, for the validation and translation of biomarker and therapeutic assets into clinical utility. They have deep expertise and capabilities in IVD development of molecular & immune-assays for ultimate product realization as diagnostic tests. Their mission is to enable faster, accurate prediction and prevention of disease, driven by the ambition to improve human health. APIS Assay Technologies is committed to realizing the clinical potential of systems biology and medicine in the diagnosis and personalization of treatment. Their products include the Breast Cancer Subtyping Kit, ESR1 Mutations Kit, Precision Expression Assays, SARS-CoV-2 IgG ELONA Kit, and SARS-CoV-2 IgG ELISA Kit. They also offer services such as contract assay development, clinical compliance services, contract manufacturing, and bioinformatics & software development.